Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Mini Review

Published on 20 Jun 2023

Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy

in Cancer Molecular Targets and Therapeutics

Teng Tu
Hongying Zhang
Huanji Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1197502

3,564 views
2 citations

Original Research

Published on 19 Jun 2023

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

in Cancer Molecular Targets and Therapeutics

Jiuhui Xu
Chenglong Chen
Kunkun Sun
Qianyu Shi
Boyang Wang
Yi Huang
Tingting Ren
Xiaodong Tang

Frontiers in Oncology

doi 10.3389/fonc.2023.1192472

2,271 views
4 citations

Original Research

Published on 19 Jun 2023

Lestaurtinib inhibits Citron kinase activity and medulloblastoma growth through induction of DNA damage, apoptosis and cytokinesis failure

in Cancer Molecular Targets and Therapeutics

Gianmarco Pallavicini
Giorgia Iegiani
Roberta Parolisi
Alessia Ferraro
Francesca Garello
Valeria Bitonto
Enzo Terreno
Marta Gai
Ferdinando Di Cunto

Frontiers in Oncology

doi 10.3389/fonc.2023.1202585

2,398 views

Review

Published on 19 Jun 2023

The role of Vps4 in cancer development

in Cancer Molecular Targets and Therapeutics

Li Juan Huang
Shi Tong Zhan
Yu Qin Pan
Wei Bao
Ye Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1203359

6,887 views
4 citations

Clinical Trial

Published on 14 Jun 2023

A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis

in Cancer Molecular Targets and Therapeutics

Gabriel Oliveira Bernardes Gil
Warne Pedro de Andrade
Paulo Henrique Costa Diniz
Farley Soares Cantidio
Izabella Nobre Queiroz
Maria Luísa Braga Vieira Gil
Conceição Aparecida Medeiros Almeida
Paola Palmer Reis Caldeira
Marcos Regalin
Agnaldo Lopes Silva-Filho

Frontiers in Oncology

doi 10.3389/fonc.2023.1202544

3,151 views
5 citations

Review

Published on 14 Jun 2023

The use of plant-derived exosome-like nanoparticles as a delivery system of CRISPR/Cas9-based therapeutics for editing long non-coding RNAs in cancer colon cells

in Cancer Molecular Targets and Therapeutics

Tatiana Hillman

Frontiers in Oncology

doi 10.3389/fonc.2023.1194350

5,264 views
11 citations

Original Research

Published on 13 Jun 2023

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

in Cancer Molecular Targets and Therapeutics

Katharine Yu
Amrita Basu
Christina Yau
Denise M. Wolf
Hani Goodarzi
Sourav Bandyopadhyay
James E. Korkola
Gillian L. Hirst
Smita Asare
Angela DeMichele

Frontiers in Oncology

doi 10.3389/fonc.2023.1192208

2,696 views

Original Research

Published on 12 Jun 2023

Early in vitro evidence indicates that deacetylated sialic acids modulate multi-drug resistance in colon and lung cancers via breast cancer resistance protein

in Cancer Molecular Targets and Therapeutics

Isaac Tuffour
Setor Amuzu
Hala Bayoumi
Iram Surtaj
Colin Parrish
Rachel Willand-Charnley

Frontiers in Oncology

doi 10.3389/fonc.2023.1145333

4,163 views
6 citations

Review

Published on 12 Jun 2023

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma

in Cancer Molecular Targets and Therapeutics

Binhao Shi
Junli Chang
Xingyuan Sun
Xiaoping Ma
Peng Zhao
Chujie Zhou
Yongjun Wang
Yanping Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1148735

2,225 views
3 citations

Original Research

Published on 08 Jun 2023

Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment

in Cancer Molecular Targets and Therapeutics

Song Liao
Jianxiong Li
Song Gao
Yuchen Han
Xinli Han
Yanan Wu
Jingyou Bi
Meng Xu
Wenzhi Bi

Frontiers in Oncology

doi 10.3389/fonc.2023.1158857

3,624 views
6 citations

Original Research

Published on 05 Jun 2023

Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients

in Cancer Molecular Targets and Therapeutics

Deliang Gong
Qingzhong Zhao
Jun Liu
Shibing Zhao
Chengfeng Yi
Jianwei Lv
Hang Yu
Erbao Bian
Dasheng Tian

Frontiers in Oncology

doi 10.3389/fonc.2023.1169430

1,951 views
1 citation

Original Research

Published on 05 Jun 2023

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

in Cancer Molecular Targets and Therapeutics

Howard Fine
Tony Reid
Scott Caroen
Bryan Oronsky
Nacer Abrouk
Nicholas Butowski

Frontiers in Oncology

doi 10.3389/fonc.2023.1176448

2,930 views
7 citations

Original Research

Published on 02 Jun 2023

Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines

in Cancer Molecular Targets and Therapeutics

Hanshuang Shao
Alan Wells

Frontiers in Oncology

doi 10.3389/fonc.2023.1163504

1,980 views
1 citation

Original Research

Published on 29 May 2023

The intervention effect of Aitongxiao prescription on primary liver cancer rats was evaluated based on high-throughput miRNA sequencing and bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Lijing Xu
Jinlai Cheng
Zhuoxian Li
Xiaoyu Wen
Yuhao Sun
Meng Xia
Jing Leng

Frontiers in Oncology

doi 10.3389/fonc.2023.1050069

3,358 views

Review

Published on 23 May 2023

Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment

in Cancer Molecular Targets and Therapeutics

Xingliang Fang
Huanrong Lan
Ketao Jin
Jun Qian

Frontiers in Oncology

doi 10.3389/fonc.2023.1149551

5,701 views
13 citations

Original Research

Published on 22 May 2023

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications

in Cancer Molecular Targets and Therapeutics

Haotian Shi
Wei Wei
Rong Peng
Haimin Chen
Nian Zhou
Lixia Wu
Wenjun Yu
Wenhao Zhao
Jian Hou
Fan Zhou

Frontiers in Oncology

doi 10.3389/fonc.2023.1185991

2,410 views
2 citations

Navigation group

Articles

Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Lestaurtinib inhibits Citron kinase activity and medulloblastoma growth through induction of DNA damage, apoptosis and cytokinesis failure

The role of Vps4 in cancer development

A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis

The use of plant-derived exosome-like nanoparticles as a delivery system of CRISPR/Cas9-based therapeutics for editing long non-coding RNAs in cancer colon cells

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Early in vitro evidence indicates that deacetylated sialic acids modulate multi-drug resistance in colon and lung cancers via breast cancer resistance protein

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma

Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment

Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines

The intervention effect of Aitongxiao prescription on primary liver cancer rats was evaluated based on high-throughput miRNA sequencing and bioinformatics analysis

Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications